Mostrar mensagens com a etiqueta Canada. Mostrar todas as mensagens

Canada Finally Stops Defending Asbestos Mining

After several decades of criticism from the international community, the Canadian government is finally stopping its unconscionable defense of the asbestos mining industry. Long an exporter of asbestos, the mineral responsible for diseases like asbestosis and mesothelioma, Canada is undergoing a change of heart as the reins of government are shifted to the Parti Québécois, led by Canada’s first female Premier, Pauline Marois.


Marois Behind New Direction on Asbestos


During her campaign, Premier Marois promised to revoke a government loan that would have allowed the Jeffrey asbestos mine in Asbestos, Quebec to restart activities. Instead of the government loan going towards dangerous asbestos mining, the government will now give communities formerly dependent on asbestos mining up to $50 million to encourage the development of other, safer industries. Quebec was the last province in Canada still exporting asbestos to other countries.


Canada’s Decision Potentially Reduces International Asbestos Use


Families of victims of mesothelioma and other anti-asbestos activists are pleased with Quebec’s announcement. Not only does the decision mean that fewer Canadian workers and their families will be exposed to asbestos, but workers internationally will also benefit from less asbestos exposure. This is because Canada has frequently blocked attempts to add chrysotile asbestos to the Rotterdam Convention, a U.N. treaty that tracks hazardous substances. With its new posture on asbestos mining, it’s unlikely that Canada will continue to try to prevent the addition of the known dangerous substance asbestos to the list.


However, while Canada is publicly changing their stance on asbestos, there are still other countries in the world that allow asbestos export and its use in manufacturing, ignoring the proven fact that asbestos is hazardous to human health and the only cause of mesothelioma, a devastating and terminal disease. The law offices of Clapper, Patti, Schweizer, and Mason fight against the irresponsible use of asbestos by representing victims of asbestos exposure and their families. To learn more about what we do and how we may be able to help you, call us toll free at 1-800-440-4262.

Posted in , , , , , | Leave a comment

Warnex will distribute mesothelioma biomarker test in Canada

It was announced this week that Warnex Medical Laboratories, a division of Warnex Inc., will be the Canadian distributor for three recently launched genetic biomarker diagnositc tests produced by Rosetta Genomics, Ltd. The tests, branded as miRview™, include a test for the detection and diagnosis of mesothelioma.

Warnex is a life sciences company providing laboratory services to the pharmaceutical and health care industries. The company will market the miRview™ products and will send samples gathered from the tests from Canada to the Rosetta Genomics laboratory in Philadelphia for analysis. Warnex has three facilities, located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

We’ve written about the miRview™ products on this site in the past. They include miRview™ mets, which can identify the primary tumor site in patients presenting with metastatic cancer; miRview™ squamous, which differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC); and miRview™ meso, which leverages microRNA’s high specificity as biomarkers to differentiate mesothelioma from other carcinomas in the lungs.

All three of the miRview tests utilize MicroRNA technology. According to Rosetta Genomics, microRNAs (or miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. This is because microRNAs have been shown to have different expression in various pathological conditions, the observation of which can provide a novel diagnostic tool for many diseases.

According to Rosetta Genomics, the miRview™ meso product is a highly accurate test that can help physicians to more easily identify mesothelioma, which can be hard to differentiate from other cancers. The test also can help rule out a meso diagnosis in patients who have been diagnosed with adenocarcinoma of the lung and who also have been exposed to asbestos, which is known to cause mesothelioma.
Tags: asbestos, biomarkers, diagnostics, mesothelioma, microRNA, miRNAs, miRview, Philadelphia, research, Rosetta Genomics, Warnex
This entry was posted on Wednesday, August 12th, 2009 at 10:34 am and is filed under News, Research/Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

View the original article here

Posted in , , , , , , | Leave a comment

Search

Swedish Greys - a WordPress theme from Nordic Themepark. Converted by LiteThemes.com.